Always fair, encouraging, and motivating.
This comment is not public.
This comment is not public.
Daniel M. Harrison, MD, is Professor of Neurology at the University of Maryland School of Medicine, where he joined the faculty in 2015. Prior to this, he served on the faculty at Johns Hopkins University School of Medicine from 2010 to 2015. He earned a BA from Rutgers University in 2000 and an MD from Albert Einstein College of Medicine of Yeshiva University in 2004. Harrison completed an internship at Long Island Jewish Medical Center in 2005, a neurology residency at New York-Presbyterian University Hospital of Columbia and Cornell in 2008, serving as chief resident at Columbia University Medical Center, and a fellowship in neuroimmunology and neuroinfectious diseases at Johns Hopkins University School of Medicine in 2010. He holds board certification in neurology from the American Board of Psychiatry and Neurology. As Director of the University of Maryland Center for Multiple Sclerosis Treatment and Research and Director of the Division of Neuro-Immunology and Multiple Sclerosis, he specializes in the diagnosis and treatment of multiple sclerosis and other autoimmune disorders affecting the brain, spinal cord, and optic nerves.
Harrison directs an active research program centered on developing and validating advanced neuroimaging techniques for multiple sclerosis, including ultra-high-field 7-tesla MRI to visualize cortical pathology, neurodegeneration, and meningeal inflammation. His laboratory also employs novel retinal imaging methods, such as adaptive optics optical coherence tomography, and machine learning approaches for image analysis and disability prediction. He participates as an investigator in the Maryland Center for Multiple Sclerosis clinical trials program. Key publications include 'Longitudinal changes in diffusion-tensor-based quantitative MRI in multiple sclerosis' (Neurology, 2011), 'Association of cortical lesion burden on 7T MRI with cognition and disability in multiple sclerosis' (JAMA Neurology, 2015), 'Leptomeningeal enhancement at 7T in multiple sclerosis: frequency, morphology, and relationship to cortical volume' (Journal of Neuroimaging, 2017), 'Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE ΔT1 mapping' (PLoS One, 2021), and 'Meningeal contrast enhancement in multiple sclerosis: assessment of field strength, acquisition delay, and clinical relevance' (PLoS One, 2024). He has been recognized as a Top Doctor in Neurology-Multiple Sclerosis by Baltimore magazine.
